Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**[D-Arg1,D-Trp5,7,9,Leu11]substance P** is a synthetic peptide analogue of substance P, designed as a broad-spectrum neuropeptide growth factor antagonist. It acts primarily as a potent inverse agonist and antagonist at multiple neuropeptide receptors, including the ghrelin receptor, tachykinin receptors, bradykinin receptors, CCK receptors, and bombesin receptors. This peptide inhibits constitutive ghrelin receptor activity (EC50 = 5.2 nM), blocks neuropeptide-induced calcium mobilization and mitogen-activated protein kinase activation, and induces apoptosis and inhibits tumor cell growth, particularly in small cell lung cancer models *in vitro* and *in vivo*.[2][4][5][7][9] Its mechanism is to broadly antagonize multiple neuropeptide signaling pathways implicated in cancer cell proliferation and survival. The compound is mostly used experimentally and in preclinical evaluation as a potential anticancer agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [D-Arg1,D-Trp5,7,9,Leu11]substance P.